I’m sure you’re tired of hearing about all the negative stuff in the news. So, I’ve decided to break the trend. Instead, on this fine Tuesday morning, I’m going to tell you the story of a remarkable man. And I’ll share how his journey with psychedelics could help you make a lot of money in the stock market.
Meet Our Hero
Heroes come in all shapes and sizes. The hero I’m talking about today comes in the form of a man named Jonathan M. Lubecky.
He honorably served in both the U.S. Marine Corps and Army from 1995 to 2009. While serving, Lubecky was deployed to active combat zones in Iraq. During the Iraq War, Lubecky’s Balad base was hit approximately 6,000 times with mortars, bombs and rockets.
It was intense…
So intense that when Lubecky returned home, he struggled with PTSD, as so many of our noble veterans unfortunately do.
But don’t worry. This story actually has a happy ending.
Lubecky’s PTSD was particularly bad. He struggled with suicidal thoughts for a long time and couldn’t make them quiet down. He reached a breaking point one day. And Lubecky put a Beretta 9MM gun to his head and pulled the trigger.
But the gun malfunctioned — and Lubecky survived. He took that as a sign that he was meant to live — to keep fighting his PTSD and win. But he was missing the tools to help him do that.
Then he started reading about MDMA on the internet and its unique ability to be “cure” PTSD in some folks.
He was intrigued. One thing led to the next. And Lubecky found himself at the Multidisciplinary Association for Psychedelic Studies (MAPS) research center in Santa Cruz, California.
There, he met with professionals and was put on an MDMA-inspired therapy routine for his PTSD.
It worked wonders.
Lubecky found that the mind-altering characteristics of MDMA calmed his PTSD in ways that traditional medicine had not. And it enabled him to feel supported in ways he hadn’t felt since before the Iraq War.
It was Lubecky’s lifesaver.
A New Generation of Lifesaving Medicines for All
As it turns out, Lubecky isn’t the only one whose life was saved by MDMA, LSD, Ketamine, or Magic Mushrooms.
All those drugs belong in a class we call “psychedelics.” And traditionally, they’ve been frowned upon by society. But things weren’t always like that…
Let’s rewind 70 years.
Back in the 1950s, Humphry Osmond led a group of pioneering psychiatrists in California that were actively experimenting with psychedelics. They found that the hallucinogenic drugs had immense therapeutic potential.
But sociopolitical backlash against “hippie culture” in the 1960s halted their research. And in 1970, psychedelics landed on Nixon’s Schedule 1 drug list.
The book was closed on psychedelic research…
Until the 2010s.
When the academics reopened that book, they discovered a world of opportunity and untapped potential.
The Data for Psychedelics Is Compelling
Two recent studies from Johns Hopkins…